Investment Rating - The report maintains a "Recommendation" rating for the veterinary medicine industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [80]. Core Insights - In January, the majority of vaccine varieties saw a year-on-year decline in batch approvals, with the Veterinary Product Index (VPI) dropping 1.8% month-on-month, marking three consecutive months of decline [2][3]. - The report highlights that the overall performance of the animal vaccine and veterinary medicine sector has been affected by high base effects from the previous year, low breeding sentiment, and the timing of the Spring Festival impacting stocking rhythms [10][57]. - The report emphasizes the importance of innovation in driving performance, noting that companies demonstrating product, marketing, or capital operation innovations have shown better financial results [71][72]. Summary by Sections Vaccine Batch Approvals - In January, most vaccine products experienced a year-on-year decline in batch approvals. For pig vaccines, the majority saw declines, with only pseudorabies and blue ear vaccines showing increases of 13.1% and 30.2%, respectively. Other vaccines like foot-and-mouth disease and porcine circovirus vaccines saw declines ranging from 20% to 50% [9][10]. - In the poultry vaccine segment, the H5N1 trivalent vaccine and Marek's vaccine saw declines of 13.8% and 25.9%, respectively, while the newcastle disease vaccine remained flat [9][10]. Veterinary Raw Materials - The VPI index averaged 66.16 in January, down 1.8% from December, with a continued downward trend observed in the prices of most raw materials. For instance, the price of florfenicol dropped by 4.5% month-on-month, while amoxicillin saw a slight increase of 0.7% [57][58]. - Year-on-year comparisons show that while some products like tylosin and tilmicosin have seen significant price increases, amoxicillin has dropped by 28.8% [58][57]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that the ongoing industry competition has led to a market environment where only innovative companies are likely to thrive. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [71][73].

内容概要：禽用疫苗是预防禽类传染病的关键生物制剂，是现代家禽养殖业疫病防控的基石。国家出台 多项政策，从全产业链构建严密监管体系，为行业筑牢质量安全防线，推动产品升级，激活市场需求。 中国作为禽类养殖与消费大国，家禽生产平稳发展，出栏量增长、存栏量优化，为禽用疫苗市场提供坚 实需求基础，催生高端疫苗市场扩容空间。禽肉产量稳健增长，拉动防疫投入，禽蛋产量调整促使精准 化免疫模式转变，共同推动禽用疫苗市场规模扩张与产品结构升级。随着畜牧业发展，兽用生物制品市 场规模扩大，2024年禽用生物制品市场复苏增长。禽用疫苗细分市场中，灭活疫苗主导，活疫苗稳基， 其他疫苗高速扩容。未来，行业将在多重驱动下高质量发展，多联多价疫苗成研发主流，新型疫苗技术 商业化加快，行业集中度提升，并向综合服务模式转型，国内企业也将加快国际化布局。 上市企业：中牧股份（600195.SH）、瑞普生物（300119.SZ）、普莱柯（603566.SH）、生物股份 （600201.SH） 相关企业：乾元浩生物股份有限公司、杭州佑本动物疫苗有限公司、金宇益康生物技术（辽宁）股份有 限公司、河南祺祥生物科技有限公司、肇庆大华农生物药品有限公司、山西 ...

（文章来源：证券日报） 证券日报网讯 2月11日，科前生物在互动平台回答投资者提问时表示，公司是一家专注于兽用生物制品 研发、生产、销售及动物防疫技术服务的生物医药企业，主要产品是非国家强制免疫猪用疫苗和禽用疫 苗。 ...

Summary of the Conference Call Company Overview - The conference call focused on **普莱柯 (Pulaike)**, a company in the **animal vaccine industry**. The discussion highlighted the company's performance in 2025 and its outlook for 2026. Key Points and Arguments Industry Context - The animal vaccine industry has faced pressure due to fluctuations in the breeding sector and internal competition, leading to a challenging environment for many companies [1][3]. - Despite these challenges, leading companies with strong R&D capabilities have managed to achieve significant growth [1]. Financial Performance - In 2025, 普莱柯 achieved a net profit of approximately **1.176 billion to 1.95 billion** CNY, representing a year-on-year growth of **90% to 110%** [3][4]. - The company reported a nearly **50% increase** in profits during the first three quarters of 2025, driven by the release of poultry vaccine production capacity and rapid growth in the pet business [1][3]. Cost Management and Efficiency - The company has focused on cost reduction and efficiency improvements, resulting in a significant decrease in operating expenses and an increase in net profit margins [1][4][5]. - Sales expense ratios have been continuously declining, indicating effective cost control measures [5][28]. Product Development and Market Strategy - The company plans to continue its focus on high-quality, efficient growth, with expectations to maintain growth in poultry and pet products in 2026 [6][37]. - New product lines, including the **H9 series** and **cash cow series**, are expected to contribute to future growth [11][23]. Market Trends and Pricing - The pricing war in the industry has shown signs of easing, particularly for certain vaccine products, although competition remains intense [10][8]. - The company anticipates that while there may still be pressure on pricing, the overall margin for leading companies remains favorable due to their competitive advantages [10]. Sales Channels and Growth - The company has established a robust distribution network, covering **25 provinces** and over **8,000 pet hospitals** [14][15]. - The pet product segment is experiencing growth rates of over **30%**, with non-medical products seeing even higher growth [15]. Future Outlook - For 2026, the company aims to achieve a net profit target of over **2 billion** CNY, with expectations of returning to historical highs [6][7]. - The poultry vaccine segment is projected to grow by **15% to 20%**, while the pet product segment is expected to exceed **50% growth** [20][37]. Research and Development - The company is actively working on new vaccine projects, including a **African Swine Fever vaccine**, with clinical trials expected to commence soon [31][32]. - The company has made significant investments in R&D to enhance its product offerings and maintain competitive advantages [32]. Challenges and Risks - The company faces ongoing challenges from industry competition and potential impacts from disease outbreaks in livestock, which could affect sales [30][19]. - The overall market environment remains volatile, with external factors influencing the breeding sector's profitability [30]. Additional Important Information - The company has implemented a more refined management approach to sales expenses, linking spending directly to sales outcomes [28]. - There is a strategic focus on expanding international business and product registrations in various countries, aiming for significant growth in export revenues [24]. This summary encapsulates the key insights from the conference call, providing a comprehensive overview of 普莱柯's current status and future prospects in the animal vaccine industry.

Core Viewpoint - The company held its first extraordinary board meeting of 2026, where several key resolutions were passed, including the approval of bank credit limits and related party transactions for the year [1][2][4][6][10]. Group 1: Bank Credit and Financing - The board approved a total bank credit limit of 5.771 billion yuan for 2026, with 1.960 billion yuan allocated to the headquarters and 3.811 billion yuan to subsidiaries [2]. - Additionally, the company and its subsidiaries will apply for project financing credit totaling 1.145 billion yuan, with 740 million yuan for the headquarters and 405 million yuan for subsidiaries [2]. Group 2: Related Party Transactions - The board approved ongoing sales of poultry vaccines and veterinary medicines to Shandong Zhongxin Food Group Co., Ltd., with an estimated transaction amount not exceeding 24 million yuan for 2026 [4][14]. - The company will also continue to purchase production raw materials from Xiamen Jindawei Group Co., Ltd., with an estimated transaction amount not exceeding 31 million yuan for 2026 [6][16]. Group 3: Internal Audit and Salary Budget - The board approved the internal audit plan for 2026 [8][9]. - The board also approved the salary budget for 2025, along with the evaluation report for the total salary for 2024 [10][11]. Group 4: Upcoming Shareholder Meeting - The board agreed to convene the second extraordinary shareholder meeting of 2026 to discuss additional matters requiring shareholder approval [11]. Group 5: Performance Forecast - The company anticipates a net profit attributable to shareholders of 148.59 million to 192.29 million yuan for 2025, representing an increase of 77.70 million to 121.41 million yuan compared to the previous year, which is a year-on-year increase of 109.62% to 171.27% [32][33]. - However, the net profit after deducting non-recurring gains and losses is expected to be between 16.90 million and 23.24 million yuan, a decrease of 38.90 million to 45.24 million yuan compared to the previous year, reflecting a year-on-year decrease of 62.60% to 72.80% [33]. Group 6: Reasons for Performance Increase - The increase in net profit is attributed to gains from investments, including the subscription of convertible bonds issued by Xiamen Jindawei Group and the abandonment of the right of first refusal for shares in Zhongpu Biopharmaceutical Co., Ltd. [37]. - The company has also optimized its marketing structure and product development to enhance operational efficiency [37].

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, indicating an expectation of the industry index outperforming the benchmark index by more than 5% in the next 3-6 months [3][80]. Core Insights - In November, the majority of vaccine products saw a year-on-year decline in batch approvals, with only the diarrhea vaccine showing a positive growth of +25.8%. Other vaccines, such as foot-and-mouth disease and pseudorabies vaccines, experienced declines ranging from -4.3% to -66.7% [8][9]. - The Veterinary Product Index (VPI) for raw materials has shown a continuous decline for two consecutive months, with a current index of 67.23, down 1.1% from the end of November. However, it is still up 2.1% year-on-year [51][55]. - The report highlights a significant differentiation in company performance within the industry, with successful companies demonstrating innovation in products, marketing, and capital operations [69][71]. Summary by Sections Vaccine Batch Approvals - In November, most vaccine products saw a decline in batch approvals compared to the previous year, with notable decreases in various pig vaccines. The only exception was the diarrhea vaccine, which increased by +25.8% [8][9]. - Cumulatively from January to November, several vaccine types, including the circular virus vaccine and the diarrhea vaccine, showed positive growth, with the circular virus vaccine increasing by +14.8% [9][10]. Veterinary Raw Material Prices - The VPI index has decreased for two consecutive months, with a current value of 67.23, reflecting a 1.1% drop from November's end. The prices of various raw materials, such as tylosin and florfenicol, have also seen declines [51][55]. - The report notes that the market sentiment for veterinary raw materials is cooling due to low demand and a lack of strong market support, leading to a weak operational state expected in the short term [55][69]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that companies with innovative capabilities are likely to perform better in the current market environment [69][71]. - Specific companies recommended for attention include Zhongmu Co., Ltd., Reap Bio, Kexin Bio, and others, which are expected to benefit from the ongoing market dynamics [71].

Core Viewpoint - TianKang Pharmaceutical Co., Ltd. continues to face declining performance in the first three quarters of the year, with high accounts receivable and low capacity utilization, raising concerns from regulatory authorities regarding its expansion plans [1] Financial Performance - Revenue and net profit have declined for two consecutive years, with revenues of 1 billion yuan, 1.055 billion yuan, and 1.052 billion yuan from 2022 to 2024, and net profits of 204 million yuan, 165 million yuan, and 153 million yuan during the same period, reflecting year-on-year declines of 18.36% and 11.20% respectively [3] - For the first nine months of 2025, the company reported a year-on-year revenue decline of 20.49% and a net profit decline of 42.44%, while comparable companies in the industry saw average revenue growth of 1.60% and net profit growth of 49.06% [4] Accounts Receivable - The company's accounts receivable at the end of the reporting periods were 338 million yuan, 377 million yuan, and 364 million yuan, accounting for 10.40%, 10.70%, and 10.95% of total assets respectively [7] - As of June 2025, accounts receivable stood at 482 million yuan, with 72.32% from government procurement clients, and overdue amounts from direct sales and distribution clients totaling 42.81 million yuan [7] Capacity Utilization and Expansion Plans - The company plans to raise 527 million yuan for various projects, including 128 million yuan for the expansion of veterinary vaccine production and 105 million yuan for the renovation of brucellosis vaccine production [9] - The current production capacity for brucellosis vaccine is 150 million doses, with capacity utilization rates of 36.02%, 43.72%, 44.44%, and 34.61% over the reporting period [11] - Regulatory authorities have questioned the necessity and rationale for expanding production given the low overall capacity utilization and have requested further analysis of market demand for the new capacity [11][12]

Investment Rating - The report maintains a "Buy" rating for the company with a target price based on the last closing price of 10.62 [1] Core Insights - The company's revenue for the first three quarters of 2025 reached 1.042 billion yuan, representing a year-on-year increase of 7.38%, while the net profit attributable to shareholders was 161 million yuan, a decrease of 4.85% year-on-year. In Q3 2025 alone, revenue was 423 million yuan, up 17.76% year-on-year, and net profit was 101 million yuan, an increase of 116.40% year-on-year [4][5] - The core products continue to see significant growth, particularly in the swine vaccine segment, with sales of foot-and-mouth disease vaccines increasing by 50% year-on-year, and diarrhea vaccines seeing a 120% increase in revenue. The company is also making steady progress in developing new vaccines, including a novel mRNA vaccine for feline infectious peritonitis [5][7] Financial Performance Summary - The company forecasts revenues of 1.569 billion yuan for 2025, 1.851 billion yuan for 2026, and 2.073 billion yuan for 2027, with net profits projected at 283 million yuan, 320 million yuan, and 335 million yuan respectively. The corresponding EPS for these years is expected to be 0.25 yuan, 0.29 yuan, and 0.30 yuan, with PE ratios of 42.57, 37.67, and 35.91 respectively [5][7][9] - The gross margin is projected to be 54.00% in 2025, with a net profit margin of 18.03% [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a steady growth in revenue and net profit, with Q1-Q3 2025 revenue at 823 million yuan (up 8.04% year-on-year) and net profit at 157 million yuan (up 47.86% year-on-year). The Q3 revenue was 264 million yuan (down 5.39% year-on-year), while net profit was 41 million yuan (up 26.69% year-on-year). The forecast for net profit from 2025 to 2027 is 205 million, 233 million, and 281 million yuan respectively, with corresponding EPS of 0.59, 0.67, and 0.81 yuan, leading to a PE ratio of 23.3, 20.5, and 17.0 times [3][4][5] Financial Performance Summary - For Q1-Q3 2025, the company's revenue from biological products was 589 million yuan (up 3.88% year-on-year), with pig-related revenue at 203 million yuan (down 19.67% year-on-year) and poultry-related revenue at 369 million yuan (up 22.71% year-on-year). The pharmaceutical segment generated 188 million yuan (up 19.91% year-on-year), with pet-related revenue at 15 million yuan (up 39.73% year-on-year) [4] - The gross margin for Q1-Q3 2025 was 60.46% (down 2.69 percentage points year-on-year), while the net margin improved to 19.09% (up 5.14 percentage points year-on-year). The expense ratio decreased to 31.24% (down 7.16 percentage points), with sales, management, and financial expense ratios at 22.39%, 8.92%, and -0.07% respectively [5] - R&D expenses for Q1-Q3 2025 reached 67 million yuan, with new veterinary drug registrations continuing to support innovation [5] Valuation Metrics - The company's total market capitalization is 4.776 billion yuan, with a current stock price of 13.80 yuan. The stock has a 52-week high of 15.79 yuan and a low of 11.28 yuan [1] - The projected revenue for 2025 is 1.216 billion yuan, with a year-on-year growth of 16.7%. The net profit for 2025 is expected to be 205 million yuan, reflecting a significant recovery from the previous year's decline [7][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a recovery in performance, with a focus on the orderly advancement of non-epidemic vaccine clinical trials. The revenue for Q1-Q3 2025 reached 1.042 billion yuan, a year-on-year increase of 7.38%, while the net profit attributable to shareholders was 161 million yuan, a year-on-year decrease of 4.85%. In Q3 alone, revenue was 423 million yuan, up 17.76% year-on-year, and net profit increased significantly by 116.40% year-on-year [2][3] - The company maintains its profit forecast for 2025-2027, expecting net profits of 188 million yuan, 352 million yuan, and 508 million yuan respectively, with corresponding EPS of 0.17 yuan, 0.32 yuan, and 0.46 yuan. The current stock price corresponds to PE ratios of 65.4, 35.0, and 24.3 times for the respective years [2] Summary by Sections Financial Performance - For Q1-Q3 2025, the company reported a revenue of 1.042 billion yuan, a 7.38% increase year-on-year, and a net profit of 161 million yuan, down 4.85% year-on-year. Q3 revenue was 423 million yuan, up 17.76% year-on-year, with net profit soaring by 116.40% year-on-year [2] - The company forecasts net profits of 188 million yuan in 2025, 352 million yuan in 2026, and 508 million yuan in 2027, with EPS projected at 0.17 yuan, 0.32 yuan, and 0.46 yuan respectively [2][3] Market Position and Growth - The company is expanding its market share in the competitive pig vaccine sector, with Q1-Q3 2025 sales of pig foot-and-mouth disease vaccines increasing by 50% year-on-year. The revenue from non-foot-and-mouth vaccines also saw significant growth, with diarrhea vaccine revenue up 120% year-on-year [3] - Direct sales channels for poultry vaccines showed strong performance, with a 40% year-on-year increase in direct sales revenue. The company is also expanding its international business, with revenue growth exceeding 16 million yuan in Q1-Q3 2025 [3] Research and Development - The company emphasizes stable operations and innovation in R&D, with R&D expenses of 96 million yuan in Q1-Q3 2025, a 9.08% increase year-on-year. The non-epidemic vaccine development is progressing, with the first clinical trial expected to begin by the end of December 2025 [4]